BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 33673870)

  • 1. Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report.
    Pham DN
    J Med Case Rep; 2021 Mar; 15(1):103. PubMed ID: 33673870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
    Goldman M; Hirsch I; Zangrilli JG; Newbold P; Xu X
    Curr Med Res Opin; 2017 Sep; 33(9):1605-1613. PubMed ID: 28644104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
    Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
    Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.
    Menzies-Gow A; Hoyte FL; Price DB; Cohen D; Barker P; Kreindler J; Jison M; Brooks CL; Papeleu P; Katial R
    Adv Ther; 2022 May; 39(5):2065-2084. PubMed ID: 35287231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.
    Chipps BE; Hirsch I; Trudo F; Alacqua M; Zangrilli JG
    Ann Allergy Asthma Immunol; 2020 Jan; 124(1):79-86. PubMed ID: 31626906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
    FitzGerald JM; Bleecker ER; Menzies-Gow A; Zangrilli JG; Hirsch I; Metcalfe P; Newbold P; Goldman M
    Lancet Respir Med; 2018 Jan; 6(1):51-64. PubMed ID: 28919200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma.
    Pelaia C; Busceti MT; Crimi C; Carpagnano GE; Lombardo N; Terracciano R; Vatrella A; Pelaia G
    Biomed Pharmacother; 2020 Sep; 129():110444. PubMed ID: 32593131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
    DuBuske L; Newbold P; Wu Y; Trudo F
    Allergy Asthma Proc; 2018 Sep; 39(5):345-349. PubMed ID: 30077185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma.
    Bleecker ER; Wechsler ME; FitzGerald JM; Menzies-Gow A; Wu Y; Hirsch I; Goldman M; Newbold P; Zangrilli JG
    Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30139780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment.
    Busse WW; Bleecker ER; FitzGerald JM; Ferguson GT; Barker P; Brooks L; Olsson RF; Martin UJ; Goldman M;
    J Allergy Clin Immunol; 2021 Jul; 148(1):266-271.e2. PubMed ID: 33609624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
    Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.
    Busse WW; Bleecker ER; FitzGerald JM; Ferguson GT; Barker P; Sproule S; Olsson RF; Martin UJ; Goldman M;
    Lancet Respir Med; 2019 Jan; 7(1):46-59. PubMed ID: 30416083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
    Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma.
    Chupp G; Lugogo NL; Kline JN; Ferguson GT; Hirsch I; Goldman M; Zangrilli JG; Trudo F
    Ann Allergy Asthma Immunol; 2019 May; 122(5):478-485. PubMed ID: 30802500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis.
    Martínez-Rivera C; Garcia-Olivé I; Urrutia-Royo B; Basagaña-Torrento M; Rosell A; Abad J
    BMC Pulm Med; 2021 Jan; 21(1):35. PubMed ID: 33478439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
    Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.
    Canonica GW; Harrison TW; Chanez P; Menzella F; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; Garcia Gil E
    Allergy; 2022 Jan; 77(1):150-161. PubMed ID: 33978983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.